Rhode Island

presented by
Health IT

Early-stage drug firm Mnemosyne thinks the market is ripe for startups in CNS diseases

Mnemosyne Pharmaceuticals gets its offbeat name from the Greek goddess of memory. It’s fitting because the Providence, Rhode Island startup is hoping to improve memory and cognitive function in patients with neuropsychiatric conditions by modulating a receptor call N-Methyl-D-Aspartate, or more commonly, NMDA. NMDA receptors have long been thought to be the master switches for […]

Devices & Diagnostics

Cardiac device maker Neograft raises $3 million

Cardiac device maker Neograft Technologies is developing new innovative medical devices focused on coronary artery bypass graft surgery, a procedure in which a blood vessel is typically removed from a patient's arm or leg and placed around a blockage in the heart to "bypass" the blockage and restore blood flow. The implanted blood vessel is called a graft. If the Angioshield is proven to be effective, its potential market is very large. About half-a-million coronary artery bypass surgeries are performed annually in the U.S. In addition, there are approximately 80,000 lower extremity bypass graft surgeries performed each year in the country. Revenue generated by products in the procedures totals about $1.6 billion annually, according to the company.